Investigational drugs for treatment of juvenile idiopathic arthritis

Angela Mauro, Donato Rigante, Rolando Cimaz

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)


Introduction: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. The improvement of knowledge about the pathogenetic mechanisms of JIA and advances in the understanding of pathways linking inflammation and autoimmunity and functions of multiple transcription factors have translated into new drug development for a tailored treatment directed to specific subpopulations of JIA patients. Areas covereds: This review provides a digest of new investigational drugs which are currently or have been recently tested for treatment of JIA, and highlights some early phase clinical trials on rilonacept, givinostat, daclizumab, tofacitinib, and sarilumab. Expert Opinion: Several studies have been focused on multiple complementary pathways driving synovial inflammation in JIA or molecules implicated in the inflammatory signature of JIA to deliver durable effects and prevent long-term complications. Since JIA is a complex disorder with multiple faces, identifying new treatment options for patients nonresponsive to the current drug armamentarium is of great relevance. A number of agents have been developed in the very last years, such as givinostat and tofacitinib, showing promising results in some cases, but trials remain in an early phase and few agents are currently under evaluation in a further phase setting. Longer-term use in possibly high numbers of patients and adequate data collection using large-scale registries are necessary to confirm clinical efficacy and provide a well-balanced overview of safety issues related to the drugs presented in this review.
Lingua originaleEnglish
pagine (da-a)1-15
Numero di pagine15
RivistaExpert Opinion on Investigational Drugs
Stato di pubblicazionePubblicato - 2017


  • Juvenile idiopathic arthritis


Entra nei temi di ricerca di 'Investigational drugs for treatment of juvenile idiopathic arthritis'. Insieme formano una fingerprint unica.

Cita questo